Join
Live feed
·
PRReleasevia Quantisnow
Citius Oncology Inc. logo
Citius Pharmaceuticals Inc. logo

Citius Oncology Highlights Phase 1 Data in an Investigator-Initiated Study of LYMPHIR® (denileukin diftitox-cxdl) in Combination with Pembrolizumab in Recurrent or Refractory Gynecologic Malignancies

ByQuantisnow·Wall Street's wire, on your screen.
CTOR· Citius Oncology Inc.CTXR· Citius Pharmaceuticals Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track CTOR (Citius Oncology Inc.), CTXR (Citius Pharmaceuticals Inc.) and more on Quantisnow.

Citius Oncology Highlights Phase 1 Data in an Investigator-Initiated Study of LYMPHIR® (denileukin diftitox-cxdl) in Combination with Pembrolizumab in Recurrent or Refractory Gynecologic Malignancies | Quantisnow